Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar cardiovascular outcomes study in type 2 diabetes after acute coronary syndrome
2009-012269-71Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), acute coronary syndrome (ACS) and cardiac morbidity comparing Aleglitazar with Placebo (2 arms). Primary endpoint: Cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Started Dec 2009; status: terminated.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)acute coronary syndrome (ACS)cardiac morbidity
Beyond the preview
Go deeper on 2009-012269-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012269-71.